Drug Eruption and Interactions - PHARMACEUTICAL REVIEW

170 DESOXIMETASONE
DESOXIMETASONE
Trade name: Topicort (Taro)
Indications: Dermatoses
Category: Corticosteroid, topical
Half-life: N/A
Clinically important, potentially hazardous interactions
with: live vaccines
Reactions
Skin
Adverse effects (sic)
(1989): Brambilla L+, Contact Dermatitis 21(4), 272
(1986): Garden JM+, Arch Dermatol 122(9), 1007
Erythema multiforme
(1996): Stingeni L+, Contact Dermatitis 35(6), 363
Photosensitivity
(1988): Stierstorfer MB+, Arch Dermatol 124(12), 1870
Eyes
Glaucoma
(1993): Aggarwal RK+, Eye 7, 664 (3 cases)
Ocular hypertension
(1993): Aggarwal RK+, Eye 7, 664 (2 cases)
DEVIL’S CLAW
Scientific names: Harpagophytum procumbens; Harpagophytum
zeyheri
Family: Pedaliaceae
Trade and other common names: Doloteffin; Grapple plant;
Griffe du diable; Harpadol; wood spider
Category: Analgesic; Anti-inflammatory
Purported indications and other uses: Oral: anorexia,
arteriosclerosis, rheumatoid arthritis, GI disorders, fibromyalgia,
loss of appetite, headache, fever, high cholesterol, menstrual
complaints, liver and gallbladder problems. Topical: rash, ulcers
Half-life: 3–6 hours
Clinically important, potentially hazardous interactions
with: anesthetics, antacids, antiarrhythmic drugs, anticoagulants,
aspirin, beta-blockers, digoxin, famotidine, histamine 2 blockers
(e.g. ranitidine), hypoglycemics, NSAIDs, ranitidine,
sympathomimetics, terfenadine, warfarin
Reactions
Skin
Adverse effects (sic)
(2003): Chrubasik S+, Rheumatology (Oxford) 42(1), 141
(2002): Chrubasik S+, Phytomedicine 9(3), 181
(2001): Gobel H+, Schmerz 15(1), 10
(2000): Chantre P+, Phytomedicine 7(3), 177
Note: Devil’s claw stimulates stomach acid production, and should
be avoided by those with stomach or duodenal ulcers. It should not
be taken by people with cardiac arrhythmias or other heart problems
DEXAMETHASONE
Trade names: Cortastat; Decadron (Merck); Dexone (Solvay);
Hexadrol
Indications: Antiemetic, Arthralgias, Dermatoses, Diagnostic aid
(many more)
Category: Corticosteroid, systemic; Corticosteroid, topical
Half-life: N/A
Clinically important, potentially hazardous interactions
with: albendazole, aminoglutethimide, aspirin, bexarotene,
carbamazepine, cyclophosphamide, dasatinib, diuretics,
ephedrine, imatinib, itraconazole, lapatinib, live vaccines,
methotrexate, phenobarbital, phenytoin, praziquantel, primidone,
rifampicin, rifampin, temsirolimus, warfarin
Reactions
Skin
Acne
(2006): Mentink LF+, Arch Dermatol 142(5), 570
(2006): Vardy J+, Br J Cancer 94(7), 1011 (15%)
(1997): Borgna-Pignatti+, JPediatr130(1), 13
Acute generalized exanthematous pustulosis
(1995): Demitsu T+, Dermatology 193, 56
Allergic reactions (sic)
(1989): Brambilla L+, Contact Dermatitis 21(4), 272
Dermatitis
(2003): Hall VC+, JAmAcadDermatol48(4), 548 (with
thalidomide)
(2002): Nucera E+, Dermatology 204(3), 248
(2000): Chew AL+, Cutis 65, 307
(1994): Whitmore SE, Br J Dermatol 131, 296 (generalized)
(1989): Rivara G+, Contact Dermatitis 21(2), 83
Edema
(1998): Berinstein TH+, Ear Nose Throat J 77(1), 40
Erythema multiforme
(2003): Hall VC+, JAmAcadDermatol48(4), 548 (with
thalidomide)
(1999): Alexiou C+, Laryngorhinootologie 78(10), 573
Exanthems
(1987): Maucher OM+, Hautarzt (German) 38, 577
Exfoliative erythroderma
(2003): Hall VC+, JAmAcadDermatol48(4), 548 (with
thalidomide)
Peripheral edema
(2002): Hempen C+, Support Care Cancer 10(4), 322
(1991): Weissman DE+, J Neurooncol 11(3), 235
Photosensitivity
(1988): Stierstorfer MB+, Arch Dermatol 124(12), 1870
Pruritus
(2004): Crandell JT, Can J Anaesth 51(4), 398
(2004): Kuczkowski KM, Anaesthesia 59(3), 308
(2003): Perron G+, Can J Anaesth 50(7), 749
(2001): Dong Y+, Chin Med J (Engl) 114(7), 764 (with
methotrexate)
(1999): Alexiou C+, Laryngorhinootologie 78(10), 573
(1988): Taleb N+, Eur J Cancer Clin Oncol 24(3), 495
Rash (sic)
(2003): Jain R+, JDermatol30(10), 713 (3 cases) (with
cyclophosphamide)
Seborrheic dermatitis
(2003): Hall VC+, JAmAcadDermatol48(4), 548 (with
thalidomide)
Striae
(1997): Borgna-Pignatti C+, JPediatr130(1), 13
(1992): Pang S+, J Clin Endocrinol 75(1), 249